JP2016513665A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513665A5 JP2016513665A5 JP2016502251A JP2016502251A JP2016513665A5 JP 2016513665 A5 JP2016513665 A5 JP 2016513665A5 JP 2016502251 A JP2016502251 A JP 2016502251A JP 2016502251 A JP2016502251 A JP 2016502251A JP 2016513665 A5 JP2016513665 A5 JP 2016513665A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- laquinimod
- transdermal patch
- patch according
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 229960004577 laquinimod Drugs 0.000 claims description 35
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims description 34
- 239000003623 enhancer Substances 0.000 claims description 13
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000035515 penetration Effects 0.000 claims description 8
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 8
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 6
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 235000006708 antioxidants Nutrition 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- -1 polyethylene terephthalate Polymers 0.000 claims description 4
- 150000003505 terpenes Chemical class 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229940087168 alpha tocopherol Drugs 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 2
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000004446 fluoropolymer coating Substances 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- NUKZAGXMHTUAFE-UHFFFAOYSA-N hexanoic acid methyl ester Natural products CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- 150000003462 sulfoxides Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361781585P | 2013-03-14 | 2013-03-14 | |
| US61/781,585 | 2013-03-14 | ||
| PCT/US2014/026807 WO2014152009A1 (en) | 2013-03-14 | 2014-03-13 | Transdermal formulations of laquinimod |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513665A JP2016513665A (ja) | 2016-05-16 |
| JP2016513665A5 true JP2016513665A5 (enExample) | 2017-05-18 |
Family
ID=50729775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502251A Withdrawn JP2016513665A (ja) | 2013-03-14 | 2014-03-13 | ラキニモドの経皮製剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20160038435A1 (enExample) |
| EP (1) | EP2968203A1 (enExample) |
| JP (1) | JP2016513665A (enExample) |
| CA (1) | CA2900977A1 (enExample) |
| HK (1) | HK1220125A1 (enExample) |
| IL (1) | IL240557A0 (enExample) |
| MX (1) | MX2015010967A (enExample) |
| WO (1) | WO2014152009A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013214909A1 (en) | 2012-02-03 | 2014-09-18 | Teva Pharmaceutical Industries Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| WO2015138887A1 (en) * | 2014-03-14 | 2015-09-17 | Teva Pharmaceutical Industries Ltd. | Transmucosal delivery of laquinimod by oral patches |
| CN112656778A (zh) * | 2020-12-28 | 2021-04-16 | 广东红珊瑚药业有限公司 | 一种压敏胶基质以及一种贴剂 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| NZ592897A (en) | 2005-10-19 | 2012-12-21 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
| KR20160013273A (ko) | 2006-06-12 | 2016-02-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| PT2234485E (pt) | 2007-12-20 | 2014-02-17 | Teva Pharma | Preparações de laquinimod estáveis |
| UA104005C2 (ru) | 2008-09-03 | 2013-12-25 | Тева Фармасьютикл Индастриз, Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
| BR112012000568A2 (pt) | 2009-06-19 | 2015-10-06 | Teva Pharma | tratamento da esclerose múltipla com laquinimod |
| RS54707B1 (sr) | 2009-07-30 | 2016-08-31 | Teva Pharmaceutical Industries Ltd. | Tretman kronove bolesti lakvinimodom |
| WO2011019375A1 (en) | 2009-08-10 | 2011-02-17 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| DE102010026879A1 (de) * | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| WO2011109531A1 (en) | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| EA201290837A1 (ru) | 2010-03-03 | 2013-05-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение волчаночного нефрита с применением лаквинимода |
| MX342001B (es) | 2010-03-03 | 2016-09-09 | Teva Pharmaceutical Ind Ltd * | Tratamiento de artritis por lupus usando laquinimod. |
| US8252993B1 (en) | 2010-05-25 | 2012-08-28 | Pioneer Hi-Bred International, Inc. | Inbred maize variety PH18FN |
| MX2013000333A (es) | 2010-07-09 | 2013-02-26 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma. |
| EP3056205A1 (en) | 2010-07-09 | 2016-08-17 | Teva Pharmaceutical Industries, Ltd. | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof |
| SG10201509831XA (en) | 2010-12-07 | 2015-12-30 | Teva Pharma | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients |
-
2014
- 2014-03-13 EP EP14724199.6A patent/EP2968203A1/en not_active Withdrawn
- 2014-03-13 MX MX2015010967A patent/MX2015010967A/es unknown
- 2014-03-13 HK HK16108223.4A patent/HK1220125A1/zh unknown
- 2014-03-13 WO PCT/US2014/026807 patent/WO2014152009A1/en not_active Ceased
- 2014-03-13 US US14/773,658 patent/US20160038435A1/en not_active Abandoned
- 2014-03-13 JP JP2016502251A patent/JP2016513665A/ja not_active Withdrawn
- 2014-03-13 CA CA2900977A patent/CA2900977A1/en not_active Abandoned
-
2015
- 2015-08-13 IL IL240557A patent/IL240557A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5542665B2 (ja) | マトリックス型経皮投与剤およびその製造方法 | |
| JP5073124B2 (ja) | ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤 | |
| TWI542368B (zh) | 含有血清素受體拮抗劑之貼劑 | |
| JP2008501805A (ja) | 薬物の皮膚送達のための接着性外皮形成製剤とそれを使用する方法 | |
| WO2009017767A2 (en) | Compositions and methods for dermally treating neuropathy with minoxidil | |
| JP2016520638A5 (enExample) | ||
| JPWO2007142295A1 (ja) | 新規テープ製剤 | |
| CN103432104B (zh) | 一种含有普拉克索的透皮贴剂 | |
| TWI687239B (zh) | 貼附劑 | |
| CN107427472B (zh) | 贴附剂 | |
| RU2004131866A (ru) | Форма для трансэпикутального введения для лечения синдрома усталых ног | |
| JP2016513665A5 (enExample) | ||
| JP2011507904A (ja) | アルプラゾラムおよび他の薬物を経皮送達するためのパッチ、製剤および関連する方法 | |
| WO2008026381A1 (fr) | Rustine pour ongle | |
| CN110022864B (zh) | 用于治疗睡眠障碍的经皮吸收制剂 | |
| CN107484412B (zh) | 含有罗匹尼罗的贴剂 | |
| JP2001058961A (ja) | 経皮吸収促進剤及び経皮吸収型製剤 | |
| JP2018535225A (ja) | 経皮薬剤送達のためのシステムおよび方法 | |
| CN102970974A (zh) | 用于治疗皮炎和牛皮癣的去炎松缩酮制剂 | |
| TW201615181A (zh) | 含依美斯汀（ｅｍｅｄａｓｔｉｎｅ）之貼布劑 | |
| JP2017190309A (ja) | リバスチグミン経皮吸収製剤 | |
| CN116712413A (zh) | 一种普拉克索透皮贴剂 | |
| JP2018104418A (ja) | 鎮痒剤を含有するロチゴチン経皮吸収型貼付製剤 | |
| JPH03112927A (ja) | 経皮吸収貼付剤 | |
| JP2017226618A (ja) | リュープロレリンの経皮吸収型製剤 |